Genzyme planning to buy back marketing rights to Synvisc
Genzyme plans to buy back the sales and marketing rights to the
osteoarthritis pain drug Synvisc from Wyeth. The transaction is ...
Your Email Address: *
Recipient(s) Email Address: *
(Separate multiple e-mail addresses with commas. Limited to 20 addresses.)
The e-mail address(es) that you supply to use this service will only be used to send the requested article.